Corrigendum: Clinical Utilization Pattern of Liquid Biopsies (LB) to Detect Actionable Driver Mutations, Guide Treatment Decisions and Monitor Disease Burden During Treatment of 33 Metastatic Colorectal Cancer (mCRC) Patients (pts) at a Fox Chase Cancer Center GI Oncology Subspecialty Clinic

Front Oncol. 2021 May 7:11:674782. doi: 10.3389/fonc.2021.674782. eCollection 2021.

¹ Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States.
² Department of Biostatistics and Bioinformatics, Fox Chase Cancer Center, Philadelphia, PA, United States.
³ Guardant Health, Redwood City, CA, United States.

Abstract

[This corrects the article DOI: 10.3389/fonc.2018.00652.].

Keywords: cfDNA; drug resistance; liquid biopsy; molecular target; precision oncology; tumor burden; tumor heterogeneity.